Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)

• Status: Terminated
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the present work is to explore and compare the diagnostic quality of sputum specimens obtained by BAL, induction with hypertonic saline (3%), and induction with INS316 in patients diagnosed with interstitial lung diseases.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• between 18 years or older

• undergone diagnostic bronchoalveolar lavage within the previous 21 days

• diagnosed with sarcoidosis or other ILD

Exclusion Criteria:

• having resting hypoxemia

• receiving corticosteroid treatment